Loading clinical trials...
Loading clinical trials...
A Multicenter, Open Label Phase II Clinical Study on the Safety, Tolerability, and Efficacy of SHR2554 Tablets in Combination With Other Anti-tumor Treatments in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Conditions
Interventions
SHR2554; SHR-A2102
SHR2554; Adabelimumab
+1 more
Locations
1
China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Start Date
October 9, 2025
Primary Completion Date
October 1, 2028
Completion Date
October 1, 2028
Last Updated
November 18, 2025
NCT06955988
NCT05132777
NCT04448379
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions